Abiopharma

🔍 Dakos Andrew (Director)

Company: Total Return Securities Fund (SWZ)

Report Date: 2026-03-24

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock at $5.96 per share (Direct)
  Date: 2026-03-24 | Code: P | equity_swap_involved: 0 | shares_owned_after: 72,119.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,000 shares of Common Stock at $5.95 per share (Direct)
  Date: 2026-03-24 | Code: P | equity_swap_involved: 0 | shares_owned_after: 73,119.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-24 | Code: H | shares_owned_after: 39,453.00

Footnotes:

• F1: Shares are held by a limited partnership in which Mr. Dakos has a beneficial interest. Mr. Dakos disclaims beneficial interest in such shares except to the extent of any pecuniary interest therein.